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ABSTRACT 
 
The human uterine cervix produces nitric oxide, which participates in the regulation of 
immunological reactions. Nitric oxide also appears to play a role in carcinogenesis and in the 
progression/regression of precancerous lesions. The cervix is a target for human 
papillomavirus (HPV) infection, the most common genital infection, and this virus is 
necessary in the connection with precancerous and cancerous lesions of the cervical 
epithelium. Local factors, such as nitric oxide, may have a role in defense against HPV 
infection and/or in the results of HPV-induced cellular changes.  
The levels of nitric oxide measured by those of its metabolites (NOx) in cervical fluid were 
compared in women with and without HPV, and different cytological and histological 
changes. Altogether, 801 women on 1033 occasions were studied. The effects of other 
relevant gynecological infections on cervical NOx levels were assessed independently and in 
association with high-risk HPV. Moreover, the expression of nitric oxide-producing 
endothelial (e) and inducible (i) nitric oxide synthase (NOS) in cervical epithelium was 
determined by Western blotting and immunohistochemistry. 
In women with cytology suggestive of HPV infection, the levels of cervical fluid NOx were 
twofold greater than in women with normal cytology. A similar difference was seen in NOx 
levels between women with (median 47.1 μmol/l) and without high-risk HPV infection 
(median 23.8 μmol/l). Cervical dysplastic lesions were associated with elevated levels of 
cervical fluid NOx; the women with low-grade lesions appeared to have the highest cervical 
nitric oxide production. 
Chlamydia trachomatis infection was associated with elevated NOx levels. Neither bacterial 
vaginosis nor candida infection affected cervical fluid NOx levels, but the number of women 
with these infections was limited.  
Cervical expression levels of eNOS and iNOS were higher in women with high-risk HPV 
infection compared with those without. Endothelial NOS was localized to vascular 
endothelium, while iNOS was mainly detected in the basal layer of squamous epithelial cells.  
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To evaluate the clinical significance of these findings, high-risk HPV-infected women without 
any treatment were followed for 12 months. At baseline, cervical fluid NOx levels were 
higher in women with persistent high-risk HPV infection compared with those with eradicated 
high-risk HPV infection. Baseline NOx levels over the 75th percentile (87 µmol/l) predicted 
high-risk HPV persistence (odds ratio 4.1). This NOx cut-off value showed 33% sensitivity 
and 90% specificity for prediction of high-risk HPV persistence. 
In conclusion, HPV infection was related with elevated levels of cervical fluid NOx as a result 
of activated expression of eNOS and iNOS proteins. High cervical fluid NOx levels were 
associated with high-risk HPV persistence, though the low sensitivity of this test to identify 
women with persistent high-risk HPV limits its clinical use.  
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INTRODUCTION 
 
It has been estimated that infection, directly or mediated through inflammation, could explain 
approximately 20% of all cancers (Aggarwal et al. 2006). This is certainly true for uterine 
cervical cancer, which, worldwide after breast cancer, is the second most common cancer in 
women (Jemal et al. 2011). It has now been conclusively documented that this form of cancer 
does not arise without persistent HPV infection (zur Hausen 2002, Bosch et al. 2007). It is 
interesting that although most women acquire genital HPV infection during their lifetimes 
(Ebrahim et al. 2005, Moscicki 2005), only a few are diagnosed with premalignant lesions or 
ultimately cervical cancer as their immunological defense fails to eradicate this infection 
(Stanley 2009). For the moment it is not known which HPV infections persist and lead to 
cervical cancer and that is why expensive and laborious follow-up of patients is needed. 
Furthermore, cervical lesions are commonly treated by means of excision, which increases the 
risk of premature labor (Jakobsson et al. 2007). Conization in many cases also represents 
overtreatment of possibly spontaneously regressing dysplastic lesions. Vaccination against the 
most common high-risk HPV types has been developed (Christensen et al. 1990, Zhou et al. 
1991, Koutsky et al. 2002), but this approach is expensive and laborious. Moreover, it has 
been postulated that other HPV types that are not covered by vaccination may become 
associated with cervical cancer when the currently known high-risk HPVs are eradicated 
(Chan et al. 2009, Merikukka et al. 2011). Therefore, it is very important to find markers that 
help to identify HPV-infected women at risk of progression of cervical lesions and ultimately 
cancer.  
An “endothelium relaxing agent” was described in 1987 (Ignarro et al. 1987, Palmer et al. 
1987). Subsequently it was shown to be nitric oxide, an uncharged gas molecule which is 
released locally at the site of the synthesis (Alderton et al. 2001, Crane et al. 2010). Nitric 
oxide has proven to be significant in various physiological and pathophysiological conditions 
(Bogdan 2001, Lala et al. 2001, Kolluru et al. 2010). It is produced by cervical cells 
(Väisänen-Tommiska et al. 2006b) and therefore it is possible that cervical nitric oxide could 
affect HPV infection. The present study was designed to elucidate this association in women. 
Moreover, cervical nitric oxide levels were assessed in women infected with Chlamydia 
trachomatis, which is an independent risk factor of cervical cancer (Madeleine et al. 2007). 
11 
 
REVIEW OF THE LITERATURE 
 
Uterine Cervix 
The human uterine cervix has to have unique properties, since it must stay rigid during 
pregnancy but open during labor (Nuutila 1999). It is composed of an extracellular matrix 
consisting predominantly of collagens with elastin and proteoglycans, and a cellular part 
containing smooth muscle cells, fibroblasts, epithelium and blood vessels (Ludmir et al. 
2000). Multilayered squamous epithelial cells line the cervix in its lower part (ectocervix), 
while a single layer of mucus-secreting glandular epithelial cells line the upper part 
(endocervix) (Roos et al. 2006) (Figure 1). The transformation zone is the area in which 
glandular epithelium changes progressively into squamous epithelium (Delvenne et al. 2007), 
and metaplastic cells at this squamo-glandular junction are vulnerable to various infections 
(Burd 2003, Delvenne et al. 2007). The basal cells, the only ones dividing actively, migrate 
upward and differentiate to keratinocytes, which, after reaching the surface of the epithelium, 
die through apoptosis (Hebner et al. 2006).  
Figure 1. A schematic illustration of components present in the human uterine cervix (with 
permission of the copyright holder. Szarewski A 2007, Altman Publishing, UK).
 
Soft, glandular
cells
Ectocervix
hard, squamous cells
Endocervical canal
squamo-glandular junction
indicated by arrow
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Cervical immune defense consists of a barrier of mucus covering epithelial cells (Johansson et 
al. 2003). These epithelial cells, together with endothelial and inflammatory cells, serve as 
antigen-presenting cells and produce mediators such as cytokines and interleukins that further 
increase inflammation. The local cervical immune response is also influenced by sex 
hormones which regulate immunoglobulin A antibody responses (Johansson et al. 2003). 
Several cervical cells, such as squamous and glandular epithelial, hematopoietic, and stromal 
cells are also capable of producing nitric oxide (Agarwal et al. 2005), a free radical gas 
involved in cervical ripening during pregnancy (Väisänen-Tommiska 2006a). 
 
Nitric oxide 
An “endothelium relaxing agent” was described in 1987 (Ignarro et al. 1987, Palmer et al. 
1987). It was soon shown that this “new” agent is detected in almost all cell types and that it 
has a role, for example, in immunology and carcinogenesis (Bogdan 2001, Coleman 2001, 
Lala et al. 2001, Korhonen et al. 2005, Ridnour et al. 2006). Nitric oxide acts as an intra- and 
intercellular messenger and it is highly diffusible both in aqueous and hydrophobic 
environments (Thomas et al. 2008).  
 
Biosynthesis  
Nitric oxide is generated from the amino acid L-arginine and molecular oxygen by nitric 
oxide synthase (NOS) (Alderton et al. 2001, Crane et al. 2010). This biosynthesis consists of 
two-stage oxidation of L-arginine to L-citrulline and nitric oxide via an intermediate,  
Nw-hydroxy-L-arginine (Figure 2). Adenine dinucleotide phosphate works as a cosubstrate 
and heme, tetrahydrobiopterin, calmodulin and flavine-adenine mononucleotide as co-factors 
in this synthesis (Alderton et al. 2001, Crane et al. 2010).  
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Figure 2. Biosynthesis of nitric oxide.  
 
 
Three NOS isoenzymes have been detected: neuronal (nNOS), endothelial (eNOS) and 
inducible (iNOS) (Pollock et al. 1991, Xie et al. 1992, Nakane et al. 1993). Of constitutive 
NOSs, nNOS is expressed mainly in neurons (Garthwaite 2008) while eNOS is expressed 
particularly in the vascular system (Shaul 2002). These NOSs are activated by intracellular 
calcium and they produce nitric oxide in nanomolar concentrations (Alderton et al. 2001, 
Shaul 2002). The third isoform, iNOS, is calcium-independent and is activated by 
inflammation (Alderton et al. 2001, Bogdan 2001, Aktan 2004). Activation of iNOS results in 
nitric oxide concentrations in the nanomolar to micromolar range (Espey et al. 2000). 
Inducible NOS is detected in various cells, such as monocytes and macrophages (Xie et al. 
1992, Thomassen et al. 2001), natural killer cells, endothelial and epithelial cells, and 
keratinocytes (Langrehr et al. 1993, Bogdan et al. 2000).  
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Table 1. Characteristics of endothelial and inducible nitric oxide synthase (NOS) that are 
important in the human uterine cervix. 
 
 Endothelial NOS Inducible NOS 
Molecular weight  140 kDa 130 kDa 
Activation Calcium - calmodulin Transcription 
Magnitude of nitric oxide 
concentration 
Nanomolar levels (10-9) Micromolar levels (10-6) 
Site of primary expression Endothelial cells Macrophages, epithelial cells 
Regulators  Acetylcholine 
Bradykinin 
Sex hormones 
Physical exercise 
 
Inflammatory mediators 
Cytokines 
Lipopolysaccharide 
Prostaglandins 
Viral components 
 
 
Assessment  
Direct measurement of nitric oxide is difficult because of its short half-life (3-5 s) and rapid 
interactions with various organic molecules (Hong et al. 2009), although several techniques, 
such as chemiluminescence, fluorometry and electrochemical methods have been employed, 
especially in scientific work (Nagano et al. 2002). Nitric oxide has also been assessed by 
optical means, electron paramagnetic resonance, magnetic resonance, and positron emission 
tomography, but these technically complex methods are not useful in clinical research (Hong 
et al. 2009). 
The Griess reaction is one of the most widely used indirect methods of nitric oxide detection. 
This colorimetric method is based on the rapid conversion of nitric oxide to its stable 
intermediates nitrate and nitrite (NOx). Nitrate in the sample is first reduced to nitrite (Green 
et al. 1982, Miranda et al. 2001). Thereafter, a two-step diazotization reaction produces a 
diazonium ion coupled to N-(1-naphthyl)ethylenediamine to form an azo product that absorbs 
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light at a 540nm wavelength (Miranda et al. 2001, Väisänen-Tommiska et al. 2003, Bryan et 
al. 2007). Food rich in nitrate elevates plasma NOx levels (Jungersten et al. 1996) and 
gastrointestinal microbes are capable of producing nitric oxide (Sobko et al. 2006). Thus, if 
nitric oxide production is detected in circulating blood, oral intake of nitrate/nitrite-containing 
food must be restricted. However, cervical fluid NOx levels are not influenced by food or 
gastrointestinal nitric oxide (Väisänen-Tommiska et al. 2003) and therefore the Griess 
reaction is a suitable method to indirectly assess nitric oxide production in the cervix. 
Different tissue NOS isoforms can be located by Western blotting and immunohistochemistry 
(Tornblom et al. 2005, Väisänen-Tommiska et al. 2006b). Nitric oxide synthase proteins can 
be measured quantitatively by Western blotting. Semi-quantitatively, NOSs can be evaluated 
by immunohistochemistry and this method enables localization of cells producing NOSs.  
 
Mechanisms of action  
Nitric oxide reacts with various molecules and proteins either directly or indirectly (Bogdan 
2001, Thomas et al. 2008). It can directly react with a target molecule, bringing about, for 
example nitrosylation of a cysteine residue, which inhibits protein synthesis. Indirect 
reactions encompass non-enzymatic oxidation of nitric oxide to reactive nitrogen species, 
which thereafter react with target molecules (Bogdan 2001, Korhonen, et al. 2005, Thomas et 
al. 2008). These various reaction mechanisms and numerous target molecules of nitric oxide 
explain its diverse and often opposing biological effects, such as its capability to both 
promote and inhibit inflammatory and carcinogenic responses (Bogdan 2001, Coleman 2001, 
Korhonen et al. 2005, Ridnour et al. 2006, Thomas et al. 2008). 
 
The effects of nitric oxide in 
The nervous system and vasculature 
Nitric oxide via nNOS takes part in inter- and intraneuronal signaling both in the brain and in 
the peripheral nervous system (Zhou et al. 2009, Steinert et al. 2010). It mediates synaptic 
plasticity and takes part in regulation of respiratory and circadian rhythms. It also participates 
in learning and memory. Neuronal nitric oxide dysfunction may be neurotoxic and lead to 
neurodegenerative disorders, such as Alzheimer’s disease, multiple sclerosis and Parkinson’s  
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disease (Zhou et al. 2009, Steinert et al. 2010). 
Nitric oxide via eNOS is an important vasoactive compound (Chatterjee et al. 2008, Kolluru 
et al. 2010). It regulates vascular tone, especially vasodilatation. It also mediates platelet 
function and has an important role in endothelial cell migration and proliferation, and 
angiogenesis. Dysfunction of eNOS has been related to occlusive cardiovascular diseases 
such as hypertension, peripheral vascular disease, stroke and coronary heart disease 
(Chatterjee, et al. 2008, Kolluru et al. 2010).  
 
Immunology 
Both eNOS and iNOS are involved in immunology, though iNOS is the most studied in this 
regard (Bogdan 2001, Coleman 2001, Ridnour et al. 2006). Various pro-inflammatory 
mediators induce iNOS activation indirectly (Drapier et al. 1988, Xie et al. 1993, Korhonen et 
al. 2005), but viral components or viral replication may also activate iNOS directly (Hori et 
al. 1999, Akaike et al. 2000). The triggering mechanisms of eNOS are unclear, but they may 
be linked to activated neutrophils (Rabelink et al. 2006). 
Nitric oxide can function as a toxic agent and eradicate infectious organisms, for example by 
inhibiting virus replication. It may regulate both innate and adaptive immunology by affecting 
the production of inflammation-related cytokines such as interleukins and interferons. In 
addition, nitric oxide modulates the function of T- and B-lymphocytes (Akaike et al. 2000, 
Bogdan 2001, Coleman 2001, Zaki et al. 2005). 
Nitric oxide may eradicate infectious organisms either directly or indirectly. Direct 
antimicrobial activity encompasses, for example, DNA mutations of pathogens, inhibition of 
protein synthesis, and enzyme activation (Bogdan 2001). Indirect reactions involve the 
formation of reactive nitrogen species (Wink et al. 1996) and interaction with reactive oxygen 
species (Bogdan 2001, Coleman 2001, Korhonen et al. 2005). Reactive oxygen species are 
produced in monocytes and macrophages during infection (Badwey et al. 1980) and their 
consequent reactions with nitric oxide lead to the formation of even more reactive radicals, 
such as peroxynitrate (Bogdan et al. 2000, Coleman 2001). These reactions, however, are 
non-selective and may also be harmful to the host cells, as seen in pneumonia caused by 
influenza virus, in which alveolar exudates as well as destruction of pulmonary architecture 
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are increased in iNOS+ mice. Furthermore, the effects of nitric oxide are not always lethal, but 
they may cause viral mutations which may lead to the generation of new resistant strains 
(Zaki et al. 2005). Thus, even if nitric oxide eradicates infectious agents, this may turn 
deleterious if toxic effects are targeted toward host cells, especially in conditions of chronic 
inflammation (Sawa et al. 2006).  
Cancer 
Evidence from in vitro and animal studies shows that nitric oxide may both promote and 
suppress cancer (Goodman et al. 2004, Ridnour et al. 2006). Both eNOS and iNOS are 
expressed by stromal as well as tumor cells (Fukumura et al. 2006, Ying et al. 2007). The role 
of nitric oxide depends on several factors, such as local microenvironment, and most 
importantly, on concentration; low levels favor while high ones suppress cancer (Goodman et 
al. 2004, Ridnour et al. 2006). Nitric oxide can promote cancer by directly damaging DNA 
and inactivating DNA-repair proteins (Lala et al. 2001, Fukumura et al. 2006). In addition, 
nitric oxide can favor tumor cell migration, invasion and angiogenesis. This may take place 
either directly or indirectly via modulation of other factors, such as vascular endothelial 
growth factor and prostaglandins (Lala et al. 2001, Fukumura et al. 2006, Ridnour et al. 
2006). On the other hand, nitric oxide may also suppress cancer, since it is capable of 
inducing tumor cell apoptosis (Fukumura et al. 2006). In fact, it has been shown that tumor 
growth progresses if the host fails to sustain nitric oxide concentrations high enough to bring 
about tumor cell apoptosis (Heller 2008). Thus, nitric oxide may have a dual effect on cancer 
and its role may change from tumor suppressor to promoter during the course of a long cancer 
pathway (Ridnour et al. 2006). 
 
Human papillomavirus infection 
 
Human papillomaviruses (HPVs) are double-stranded DNA viruses with eight genes encoding 
six early proteins and two capsid proteins (Baker et al. 1991). About 150 different HPV types 
have been recognized and more genotypes are being detected (zur Hausen 1996, Stanley et al. 
2007). Roughly 40 HPV types are capable of infecting the genital mucosa. The infection can 
be subclinical (Moscicki 2005, Trottier et al. 2006a) or manifest with genital warts, vulvar, 
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vaginal and cervical intraepithelial neoplasia, and ultimately cancer (Parkin et al. 2006, 
Insinga et al. 2008). Human papillomaviruses can be divided into low-risk and high-risk HPV 
genotypes depending on their oncogenic potential (Bosch, et al 2003). Low-risk HPVs cause 
benign genital warts and low-grade dysplastic lesions, while high-risk HPVs can cause both 
low- and high-grade vulvar, vaginal and cervical lesions (Munoz et al. 2003, Clifford et al. 
2006). It has been suggested that cervical cancer does not arise without the presence of 
persistent high-risk HPV infection (Bosch et al. 2002, zur Hausen 2002). High-risk HPV 16 
and 18 are the most common genotypes found in all genital HPV-related malignancies 
(Stanley 2010a). 
 
Detection 
In cervical cells HPV induces typical cytological changes such as koilocytosis and 
dyskeratosis which can be detected in Pap smears (Purola et al. 1977). The sensitivity of Pap 
smears to revel lesions similar to or more severe than CIN 2 (cervical intraepithelial neoplasia 
grade 2) is lower compared with HPV tests (Arbyn et al. 2006) and thus the use of HPV tests 
has become more popular (Schiffman et al. 2011). Human papillomavirus tests can detect 
HPV viral DNA or RNA (Sandri et al. 2006, Dockter et al. 2009). DNA-based tests detect the 
presence of the HPV virus genome, whereas RNA tests detect the expression of messenger 
RNA of oncogenes E6 and E7. Two of the most common DNA-based HPV tests are the 
polymerase chain reaction-utilizing target amplification method (Roche Amplicor, 
Branchburg, NY, USA) and the hybrid capture method using signal amplification (Digene 
Corporation, Gaithesburg, MD) (Iftner et al. 2003). These both tests detect the same 13 high-
risk HPV genotypes (Sandri et al. 2006, Carozzi et al. 2007). 
 
Epidemiology  
Human papillomavirus infection is the most common genital infection. In sexually active 
women the lifetime risk of infection is 80% (Ebrahim et al. 2005, Moscicki 2005). The 
incidence is highest after the initiation of sexual life (Moscicki et al. 2001, Kahn et al. 2002) 
and another incidence peak is seen in postmenopausal women (Burchell et al. 2006), the latter 
probably representing reactivation of an earlier infection (Burchell et al. 2006, Trottier et al. 
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2006b). The prevalence of HPV infection among women ranges from 2 to 40% (Bosch et al. 
2003, Baseman et al. 2005). In a Finnish cohort the prevalence of HPV was found to be 33% 
among first-year University students (Auvinen et al. 2005). Biological factors such as 
inadequate production of cervical mucus, and abundant glandular and metaplastic epithelium 
make young women more susceptible to HPV (Kahn et al. 2002, Moscicki 2005, Burchell et 
al. 2006, Delvenne et al. 2007).  
 
Natural course and immunology of human papillomavirus infection 
Most HPV infections are transient and 90% of women without any immune compromise 
eradicate the virus within 2 years (Moscicki et al. 2004, Stanley 2010b, Woo et al. 2010). 
Increasing age (Ho et al. 1998), high virus load (Maucort-Boulch et al. 2010), infection with 
HPV 16 (Richardson et al. 2003) or with multiple HPV types (Ho et al. 1998, Nielsen et al. 
2010), and smoking (Matsumoto et al. 2010) are associated with longer clearance time. 
Moreover, some women are genetically more vulnerable to HPV persistence (Wang et al. 
2009, Ferguson et al. 2011). 
Human papillomavirus infection is initiated from the basal layer of squamous cervical cells in 
which the number of viral copies is kept low (Burd 2003, Hebner et al. 2006). The low 
number of viral copies helps HPV to avoid the host immune system. Human papillomavirus is 
incapable of amplifying its DNA and thus it needs host cell DNA machinery. Viral early 
proteins take part in this genome replication. The expression of early proteins E6 and E7, also 
called as oncoproteins, delays normal cell maturation and arrests cervical cell apoptosis, 
which leads to immortalizing of infected cells (Burd 2003, Hebner et al. 2006). At the surface 
of the epithelium the number of viral copies is high and capsid proteins L1 and L2 are 
synthesized. They are needed for viral genome encapsulation and finally new virus particles 
are shed to initiate a new infectious cycle (Woodman et al. 2007).  
The local immune system in the cervix is important for HPV clearance (Stanley 2006, Song et 
al. 2008). This clearance is associated with T-helper-1-type cytokines (Stanley 2006, Song et 
al. 2008, Syrjänen et al. 2009), including interferon-γ and tumor necrosis factor-α, whereas T-
helper-2 cytokines such as interleukin-10 and interleukin-13 are inhibitory as regards cell-
mediated responses (Spellberg et al. 2001) and thus for virus eradication (Stanley 2006). 
Cleared HPV infection is associated with humoral antibodies against the infected HPV 
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genotype, but these antibodies are not protective against other HPV genotypes (Palmroth et 
al. 2010).  
 
Cellular and dysplastic changes associated with human papillomavirus infection  
 
At the cellular level, HPV DNA exists typically in an episomal form in low-grade lesions, 
whereas integration into the host genome increases in parallel with lesion grade (Figure 3) 
(Munger et al. 2004, Woodman et al. 2007). High-grade lesions are associated with high 
expression of oncogenes E6 and E7, which favors high-risk HPV persistence, a key factor in 
neoplastic transformation of cervical cells (Burd 2003, Munger et al. 2004, Hebner et al. 
2006). 
Approximately 66–75% of women with detectable high-risk HPV infection do not have any 
cytological abnormalities, and only a small proportion of women are diagnosed with 
dysplastic lesions (Schiffman et al. 2011) (Figure 3). Squamous cell lesions are histologically 
divided into CIN grades 1, 2 and 3 (Kumar et al. 2010). The cellular hallmarks involve 
atypical cell proliferation with altered size, shape, and polarity, an increased number of 
mitoses and disturbed epithelial architecture. In CIN 1 lesions morphological changes are 
mild and restricted to the lowest 1/3 of the epithelium, whereas in CIN 2 lesions the changes 
extend to 2/3 of the epithelium, and in CIN 3 the entire epithelial thickness is involved. 
Cancer arises when the basal membrane is breached and infiltrative growth or metastases 
exist (Kumar et al. 2010). Adenocarcinoma (and its precursors) arises from cervical glandular 
cells and it accounts worldwide for 10–20% (Castellsague et al. 2008) and in Finland 30% 
(Finnish Cancer Registry) of all cervical cancers. In contrast to squamous epithelial cancer, 
the incidence of adenocarcinoma is increasing (Dahlström et al. 2010).  
Of low-grade lesions only some are caused by high-risk HPV, whereas practically all high-
grade lesions are accompanied by the presence of high-risk HPV (Table 2). The time between 
high-risk HPV infection and the development of CIN 3 is 3–5 years, but the progression to 
invasive cancer takes a further 10–20 years (Stanley 2010b).  
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Figure 3. Different stages of human papillomavirus-related cervical lesions. The arrows show 
the direction of viral replication from basal to upper layers of the epithelium. New viruses are 
shed and they initiate a new infection cycle. (With a permission of the copyright holder, 
Woodman, et al. 2007). 
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Table 2. Proportion of high-risk human papillomavirus (HPV) infections in connection with 
different cytological changes and cervical intraepithelial neoplasias (CIN). 
 
 Cytology Histology 
 Normal ASC-US LSIL HSIL CIN 1 CIN 2 ≥ CIN 3  
Percentage of 
high-risk HPV 
infected  
101 32-782,3 29-922,3 75-972,3 50-884,5 70-904,5 98.8-1005 
 
(1de Sanjose et al. 2007, 2 Evans et al. 2006, 3Clifford et al. 2006, 4Castellsague 2008, 5Castle 
et al. 2010). 
ASC-US: atypical squamous cells of undetermined significance 
LSIL: low-grade squamous intraepithelial neoplasia 
HSIL: high-grade squamous intraepithelial neoplasia 
 
All cervical lesions are dynamic and may regress, persist, or progress (Jordan et al. 2009). Of 
CIN 1 lesions over 90% regress spontaneously (Moscicki et al. 2004) and a risk for cervical 
cancer is estimated to be as high as 1.9% (Pretorius et al. 2006). As lesion severity increases 
the tendency to regress decreases. It has been evaluated that 43% of CIN 2 lesions and 32% of 
CIN 3 lesions regress spontaneously (Ostör et al. 1993). However, in young women these 
numbers are much higher, since 68% of women of < 24 years of age experience resolution of 
CIN 2 lesion within 3 years (Moscicki et al. 2010). High-grade lesions are always treated 
nowadays and thus it is impossible to assess the true cancer risk associated with these lesions. 
In an untreated cohort 31.3% of women with CIN 3 lesions developed cervical cancer within 
30 years (McCredie et al. 2008). 
Cervical lesions are detected by colposcopy and directed biopsies and the most common 
treatment modality is Loop-conization, in which a part of the cervix is removed. This leads to 
activation of the immune system which results in HPV eradication in almost all cases within 
one year (Kim et al. 2009).  
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Other relevant gynecological infections 
 
Chlamydia trachomatis 
Chlamydia trachomatis is the most common sexually transmitted bacterium (Manavi 2006). 
Diagnosis of Chlamydia trachomatis infection is currently based on detection of its ribosomal 
RNA in the cervix or urine. The infection may be clinically asymptomatic or cause ascending 
pelvic inflammatory disease (Manavi 2006). Women infected with Chlamydia trachomatis in 
20–60% of cases are co-infected with HPV (Denks et al. 2007, Keegan et al. 2009, Verteramo 
et al. 2009), and though Chlamydia trachomatis infection is an independent risk factor of 
cervical cancer (Paavonen et al. 1999, Anttila et al. 2001, Smith et al. 2002b) it may also 
serve as a cofactor of high-risk HPV-induced carcinogenesis (Samoff et al. 2005). 
 
Bacterial vaginosis 
Bacterial vaginosis is a common genital infection in women of reproductive age. The 
prevalence varies between 8–23% (Marrazzo 2011). Overgrowth of Gardnerella vaginalis, 
Mycoplasma hominis, anaerobic bacteria, and a lack of normal lactobacilli flora, are 
characteristics of bacterial vaginosis (Tokyol et al. 2004, Fitzhugh et al. 2008). Diagnosis is 
based on the presence of a milky homogeneous vaginal discharge with pH a higher than 4.5, a 
fishy odor after the addition of potassium hydroxide, and the presence of clue cells in Pap 
smears (Amsel et al. 1983, Davis et al. 1999). Clue cells are squamous cells that are 
completely covered by coccobacilli. Despite bacterial overgrowth, bacterial vaginosis is not 
accompanied by neutrophils (Fitzhugh et al. 2008). Spontaneous clearing as well as recurrent 
infections are common (Marrazzo 2011). Bacterial vaginosis increases the risk of preterm 
birth (Kurki et al. 1992, Kekki et al. 2001). It also enhances the risk of acquiring HIV 
infection (Thurman et al. 2010), but probably not HPV (Nam et al. 2009) and thus the 
association of bacterial vaginosis with cervical changes is controversial (Boyle et al. 2003, 
Nam et al. 2009).  
 
24 
 
Candida  
Candida is a common cause of vaginitis, with prevalence of 10% (Spence et al. 2007) and of 
which Candida albicans accounts for 85–90% of cases (Walker et al. 2000). Clinical 
symptoms are abnormal vaginal discharge and itching, but many women are asymptomatic 
(Sobel 2007, Spence et al. 2007, Fitzhugh et al. 2008). Diagnosis can be carried out 
microscopically by observing the presence of fungal organisms in wet mounts or by detecting 
yeast forms with long pseudohyphae in Pap smears (Audisio et al. 2001, Fitzhugh et al. 
2008). Candida is not an independent risk factor of high-grade cervical abnormality (Roeters 
et al. 2010). However, women with concomitant candida and ASC-US in Pap smears more 
often have high-risk HPV compared with women with ASC-US only (Hall et al. 2009). 
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AIMS OF THE STUDY 
 
The present study was undertaken to evaluate the possible involvement of cervical nitric 
oxide release in cases of HPV infection (Figure 4). 
Specific aims were to compare  
cervical fluid nitric oxide metabolite levels in women with and without 
1. typical HPV-induced cytological abnormalities 
2. high-risk HPV  
3. high-risk HPV-associated cervical lesions 
4. Chlamydia trachomatis, bacterial vaginosis and candida infection 
5. The expression of eNOS and iNOS in the cervices of women with and without high-risk 
HPV  
6. The cervical fluid nitric oxide metabolite levels in women with persistent versus regressed 
high-risk HPV 
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Figure 4. Possible associations between nitric oxide and human papillomavirus (HPV) 
infection. 
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SUBJECTS AND METHODS 
 
Subjects 
 
The study was conducted at Helsinki University Central Hospital and approved by the Ethics 
Committee of the Department of Obstetrics and Gynecology. Altogether, 801 women on 1033 
occasions were studied during the period of 2006–2009 (Table 3). Some women took part in 
both Studies II and V. The women either participated in a screening program or visited 
outpatient departments of obstetrics and gynecology, or clinics of sexually transmitted 
diseases. The presence of cervical high-risk HPV was assessed in 504 women (Studies II–V). 
Pregnant women, women under 18 years of age (Studies I-V), and women with cervical 
bleeding were excluded from the study (Studies I–III, V). Loop conization was a 
contraindication for predictive analyses. During the study period all lesions of ≥ CIN 1 were 
treated in women over 30 years of age and in women < 30 years of age CIN 1 lesions were 
predominantly followed without treatment.  
 
Table 3. Clinical characteristics of the women studied.  
Study I II III  IV V 
Number of women 297 328 39 86 283 
Age, mean ± SE 
Range 
36.9 ± 11.8  
18–61 
35.2 ± 11.4 
18–69 
27.6 ± 1.1 
18–47 
38.2 ±1.0 
18–58 
33.4 ± 11.0 
18–64 
Nulliparous  152 (51%)  168 (51%) 30 (77%) 33 (38%) 128 (45%) 
Use of oral 
contraceptive 
68 (23%) 117 (36%) 21 (54%) 19 (22%) 126 (45%) 
Use of intrauterine 
device  
17 (6%) 54 (16%) 3 (8%) 16 (19%) 35 (12%) 
Postmenopausal  
Use of hormone 
replacement therapy  
20 (7%) 
17 (85%) 
29 (9%) 
24 (83%) 
0 
0 
7 (8%) 
5 (71%) 
28 (10%) 
19 (68%) 
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Study specimens 
Cervical fluid  
Before any other sampling or manipulation of the cervix, fluid samples were collected by 
keeping a Dacron polyester swab in the cervical canal for precisely 20 seconds under visual 
control. Thereafter, the swab was flushed in 1.5 ml of physiological saline for 2 min. The 
saline solution was kept frozen (-21 ○C) until analyzed (Väisänen-Tommiska et al. 2003).  
 
Pap smears 
Pap smears were collected at routine screening visits or on a clinical basis if needed. Cells 
were collected from the vagina, around the internal os of the cervical canal, and inside the 
cervical canal. Cytological classification was based on the Bethesda 2001 system (Smith 
2002a). Low-grade cytological squamous changes covered diagnoses of ASC-US and LSIL. 
None of the studied women had glandular low-grade atypia. The high-grade category covered 
“atypical squamous cells – cannot exclude high grade intraepithelial neoplasia” (ASC-H), 
“atypical glandular cells – favors neoplasia”, and HSIL. In Study I Pap smears were evaluated 
for specific HPV-associated changes, such as parakeratosis, dyskeratosis, angular nuclei, and 
amplifolia.  
 
Cervical biopsies  
Cervical biopsy samples, taken by Schumacher punch biopsy forceps (Stiefel Laboratories, 
Wooburn Green, Bucks, UK), were collected at the sites which stained positively with acetic 
acid at colposcopy. The samples were studied microscopically, classified according to CIN 
classification (Kumar et al. 2010) and grouped as normal, CIN 1, and ≥ CIN 2 (Studies II, IV 
and V). After 1–4 diagnostic biopsy samples two research samples were taken. From women 
undergoing surgical procedures the biopsy samples were collected under general anesthesia 
from the squamo-glandular junction at 6 and 12 o`clock positions before possible cervical 
manipulation (Study IV). One research sample was snap-frozen in liquid nitrogen and stored 
at -80○C for subsequent Western blotting, and the other one was fixed in formalin, dehydrated 
and embedded in paraffin for immunohistochemistry. 
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Detection of infection 
 
High-risk human papillomavirus 
Samples taken to the presence of high-risk HPV were collected by inserting a specific brush 
(DNAPAP Cervical Sampler Hybrid Capture 2, Digene Corporation, Gaithersburg MD, USA, 
or Roche AMPLICOR HPV test, Molecular Diagnostics, Roche Molecular Systems, Inc., 
USA) into the cervical canal. The brush was either left at the bottom of the transport tube 
(Hybrid Capture 2) or removed after flushing into the transport liquid (AMPLICOR). Both 
samples were stored at room temperature for a maximum of three weeks before analysis. 
Both tests detect the same 13 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68) without differentiating between them. Hybrid capture 2 is a semi-automated test 
involving long single-stranded RNA for hybridization with high-risk HPV DNA in the 
sample. Thereafter, these RNA-DNA hybrids bind to specific immobilized on microplates.  
The AMPLICOR HPV test utilizes the polymerase chain reaction. Initially, the DNA strands 
are dissociated by heating the sample, then a set of consensus primers hybridizes with an HPV 
DNA sequence of the conserved region of the L1 gene and initiates polymerization via a heat-
stable DNA polymerase. This polymerization is cycled 20–40 times, yielding about 1 billion 
copies after 30 thermal cycles. Both tests were used in Study II, while in the rest of the studies 
only the AMPLICOR HPV test was used. 
 
Chlamydia trachomatis 
Chlamydia trachomatis was detected by using a commercial test (Gen-Probe Incorporated, 
San Diego, USA). Cervical samples were collected by rotating a specific swab (Aptima 
Unisex Swab Specimen Collection Kits, Gen-Probe Incorporated, San Diego, USA) in the 
cervical canal or by collecting 2 ml of in initial urine stream in a transport tube (Aptima Urine 
Specimen, Gen-Probe Incorporated, San Diego, USA). The presence of Chlamydia 
trachomatis was assessed by isothermal transcription-mediated amplification of ribosomal 
RNA. The samples were manipulated to release Chlamydia trachomatis-specific RNA, 
followed by its amplification and formation of an RNA:DNA hybrid which is measurable in a 
luminometer (Gen-Probe Incorporated, San Diego, USA). This technique is capable of 
detecting a single copy of Chlamydia trachomatis RNA in the sample.  
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Bacterial vaginosis and candida 
Women were judged to have bacterial vaginosis if clue cells were present in Pap smear. Clue 
cells are cells which are completely covered by coccobacilli. Infection of candida was based 
on cytological evaluation as well, and women showing typical pseudohyphae or fungal 
orgnanisms in Pap smear were judged to have candida infection.  
 
Measurement of nitric oxide  
 
Metabolites 
Concentrations of NOx were measured spectrophotometrically from the cervical fluid 
samples. The samples (500 μl) were centrifuged (2200 × g, for 10 min at + 4○C) and 
thereafter nitrate reduction was carried out by incubating 125 μl of the sample with 5 μl (10 
U/ml) nitrate reductase (Boehringer Mannheim), 5 μl (20 mM) nicotinamide adenine 
dinucleotide phosphate-oxidase (Boehringer Mannheim), 5 μl (1 mM) flavinine adenine 
dinucleotide (Boehringer Mannheim), and 50 μl phosphate-buffered saline for 15 minutes. To 
avoid interference of remaining nicotinamide adenine dinucleotide phosphate-oxidase with 
the chemical detection of nitrite it was removed by incubation with 1.25 μl (3.75 mM) lactate 
dehydrogenase (Boehringer Mannheim) and 100 μl (15 mM) pyruvate (Sigma-Aldrich, St. 
Louis, MO, USA) for 10 minutes. Total nitrite was then measured by adding Griess reagent to 
the supernatant. This was prepared by mixing equal volumes of 10%  
p-aminobenzenesulfoamide (Sigma-Aldrich, St. Louis, MO. USA) in 25% phosphoric acid 
(Riedel-de Haen AG, Seelze, Germany) and 1% N-(1-naphthyl)-ethylenediamine 
dihydrochloride (Sigma-Aldrich, St. Louis, MO, USA) immediately before use (Väisänen-
Tommiska et al. 2003). The Griess reaction was carried out in duplicate, and absorbance was 
read at a wavelengths of 546 nm against sodium nitrate (Merck) standards (0, 1.25, 2.5, 5, 
12.5, 25 and 50 μmol/l) prepared in water and processed in the same way as the samples. An 
individual blank was prepared for every sample, and the absorbance obtained from the blank 
was subtracted from that of the sample. The detection limit of the assay was 0.8 μmol NOx/l 
of cervical fluid, and intra- and interassay coefficients of variation were 1.6 and 2.4%, 
respectively (Väisänen-Tommiska et al. 2003).  
31 
 
Synthases 
Western blotting 
Western blot analysis was carried out to assess the expression of eNOS and iNOS proteins in 
the cervical tissue samples. The frozen biopsy samples were crushed and homogenized with 
Precellys 24 (Bertin Technologies, Villeurbanne, France) in buffer containing 50 mM Tris-
HCl, pH 8.0, 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulfate (Sigma-Aldrich, St Louis, MO, USA). The 
samples were clarified by centrifugation and stored at -140 ºC until used. Total protein 
concentrations were quantified by using Bio-Rad Protein Assays (Bio-Rad Laboratories, 
Hercules, CA, USA). Samples containing 25 µg of protein were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis at 150 V for 1 h (3–8% Tris-Acetate SDS-PAGE 
gel; Invitrogen, Carlsbad, CA, USA) and the proteins were transferred to a polyvinylidene 
fluoride membrane (pore size 450 µm; 15 V for 35 min) by wet blotting. The membranes 
were blocked in 3% bovine serum albumin (Sigma-Aldrich, St Louis, MO, USA) at room 
temperature for 1h. Primary antibody incubations (mouse monoclonal eNOS/NOS Type III, 
1:2500 and iNOS/NOS Type II, 1:10000, BD Transduction Laboratories, Franklin Lakes, NJ, 
USA) were carried out at +4 ºC overnight. Polyclonal rabbit anti-mouse immunoglobulins 
coupled to horseradish peroxidase (DAKO, Glostrup, Denmark) were used as secondary 
antibodies. Specific signals were detected by means of an enhanced chemiluminescence 
system (ECL Plus, Amersham GE Healthcare, Little Chalfont, UK) according to the 
manufacturer’s instructions and visualized by exposure to ECL hyperfilm (Amersham, UK). 
Signal intensity was quantified by densitometry (Syngene, Synoptics Limited, Cambridge, 
UK). 
Human umbilical vein endothelial cell lysates (Biomedicum Helsinki, Finland) and lysates of 
interferon-γ/lipopolysaccharide-treated mouse macrophages (Transduction Laboratories, 
USA) were used as positive controls for eNOS and iNOS, respectively. Actin (C-2, 1:750; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as a protein loading control.  
 
Immunohistochemistry 
Paraffin sections (5 µm) were deparaffinized and pretreated by heating in a microwave oven 
in 0.01 M citric acid buffer (pH 6.0) for antigen retrieval. Next, immunohistochemistry was 
carried out with the help of a Labvision autostainer (LV-1; Thermo Fisher Scientific Inc., 
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Fremont, CA, USA) and a PowerVision+TM Poly-HRP IHC Detection System (Leica 
Biosystems Newcastle Ltd., UK) according to the manufacturers’ instructions. The sections 
were sequentially incubated with 3% hydrogen peroxide, pre-blocking solution, primary 
antibodies (polyclonal rabbit antibodies for eNOS and iNOS, Thermo Fisher Scientific; 1:400, 
RT, 60 min), post-blocking solution, and poly-HRP IgG polymer for post-blocking. Tris-
buffered saline with Tween, or aqua, was used for washing. Antigens were localized by using 
diaminobenzidine tetrahydrochloride Plus Substrate. The sections were counterstained with 
Mayer`s hematoxylin solution (Merck) rinsed with aqua and manually mounted.  
Sections of umbilical cord were used as positive controls for both eNOS and iNOS. Negative 
control measures included replacing primary antibody with rabbit IgG (Negative Control for 
Rabbit IgG Ab-1, Thermo Fisher Scientific) and incubating slides without primary antibody.  
 
Statistical analyses 
 
Baseline clinical data were analyzed by means of the Chi-square test and Fisher`s exact 
probability test. The NOx data were expressed as medians with 95% confidence intervals 
(CIs) and NOS data as mean ± standard error (SE) with 95% CI. Neither NOx nor NOS data 
were normally distributed and thus significances were tested by means of the Mann–Whitney 
test or the Kruskall–Wallis test with Bonferroni correction for multiple comparisons. 
Correlations were assessed by calculating Spearman`s correlation coefficient. Logistic 
regression analyses were performed to study the prediction of high-risk HPV persistence 
according to different variables. All tests were two-sided and processed by using SPSS 14 
(Chicago, IL, USA) or PASW 18 (IBM Corporation, New York, USA) software. Probability 
values < 0.05 were considered statistically significant. 
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RESULTS 
 
The main data are presented here; details are shown in the original publications. 
 
Clinical characteristics 
The women with abnormal cytology suggestive of HPV infection were more often nulliparous 
compared with the women with normal cytology (Study I). Of the women assessed for the 
presence of high-risk HPV, 290 (58%) were infected and 214 (42%) were non-infected 
(Studies II–V). Those with high-risk HPV were younger, more often used oral contraceptives, 
and were more often nulliparous. The women infected with Chlamydia trachomatis were 
younger compared with non-infected women (Study III).  
 
Nitric oxide and human papillomavirus infection  
Cervical fluid NOx levels ranged from undetectable to 242 µmol/l. Among women with 
abnormal cytology suggestive of HPV infection, median NOx levels were 102% higher than 
in women with normal cytology (22.5 μmol/l, 95% CI: 14.6–31.9 vs. 11.0 μmol/l, 95% CI: 
8.0–16.7) (p < 0.001). The women with high-risk HPV infection (combined data from Studies 
II and V) showed significantly higher NOx levels (47.1 μmol/l, 95% CI: 38.7–55.6) than the 
women without such infection (23.8 μmol/l, 95% CI: 20.4–26.7) (p < 0.0001) (Figure 5). In 
subgroup analyses, clinical variables such as parity, use of oral contraceptives and intrauterine 
devices, did not affect NOx levels (Study II).  
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Figure 5. Levels of cervical fluid nitric oxide metabolites (NOx) in women with and without 
high-risk human papillomavirus (HPV) infection (Studies II and V).  
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Nitric oxide in cytological and histological lesions associated with human papillomavirus 
infection  
In women with normal cytology those with high-risk HPV infection had higher NOx levels 
(45.2 μmol/l, 95% CI: 31.66–1.6) than women without such infection (21.5 μmol/l, 95% CI: 
17.0–26.2) (p = 0.002). High-risk HPV infection was accompanied by elevated NOx levels in 
women with low-grade cytological changes (57.0 μmol/l, 95% CI: 48.7–63.0 vs. 26.0 μmol/l, 
95% CI: 17.4–41.3) (p = 0.002). In women with CIN 1, those infected with high-risk HPV 
had higher NOx levels (48.8 μmol/l, 95% CI: 42.95–6.7) compared with non-infected women 
(23.4 μmol/l, 95% CI: 23.6–41.2) ( p = 0.003) (Figures 6,7, Studies II and V). Women with 
high-risk HPV infection and low-grade cytological changes had higher NOx levels (57.0 
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μmol/l, 95% CI: 48.7–63.0) than those with high-grade changes (28.8 μmol/l, 95% CI: 1.2–
70.4) (p = 0.001) (Figure 6, Studies II and V).  
 
Figure 6. Levels of cervical fluid nitric oxide metabolites (NOx) in women with and without 
high-risk human papillomavirus (HPV) infection and with normal or abnormal cervical 
cytology (Studies II and V).  
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Figure 7. Levels of cervical fluid nitric oxide metabolites (NOx) in women with and without 
high-risk human papillomavirus (HPV) infection and with normal or abnormal cervical 
histology (Studies II and V). NS = non-significant. 
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Nitric oxide metabolites and other relevant gynecological infections 
Women infected with Chlamydia trachomatis had higher NOx levels (37.5 μmol/l, 95% CI: 
6.1–50.9) than women without such infection (19.7 μmol/l, 95% CI: 5.6–30.0) (p = 0.02) 
(Study III). Neither bacterial vaginosis nor candida infection had an effect on cervical fluid 
NOx levels, but the number of studied women with these infections was limited (Table 4, 
Study II). 
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Table 4. Levels of cervical fluid nitric oxide metabolites [NOx median µmol/l (95% CI)], in 
women with (+) and without (-) high-risk human papillomavirus (HPV) and Chlamydia 
trachomatis, bacterial vaginosis, and candida infections. 
1
p = 0.02, 2p = 0.2 
 
 
Nitric oxide synthase and high-risk human papillomavirus infection 
High-risk HPV infection was associated with elevated expression of both eNOS and iNOS 
proteins in Western blot analysis (eNOS: mean 33.8 ± 5.6, 95% CI: 22.5–45.1 vs. 20.2 ± 6.8, 
95% CI: 6.1–34.3, p = 0.007; iNOS: mean 12.0 ± 2.4, 95% CI: 7.1–16.9 vs. 5.6 ± 1.8, 95% 
CI: 2.0–9.2, p = 0.003) (Figure 8, Study IV). Positive controls for eNOS (human umbilical 
vein endothelial cell lysates) and iNOS (lysates of interferon-γ / lipopolysaccharide-treated 
mouse macrophages) showed bands in Western blots as expected.  
 
 
 
 
 
 
 
Subgroups  high-risk HPV + high-risk HPV - p 
NOx n NOx n 
Chlamydia trachomatis + 27.2 (17.1-50.9) 14 50.91  5 0.05 
Chlamydia trachomatis - 36 3 18.71 (2.0-28.6) 15 0.2 
Bacterial vaginosis + 36.2 (24.3-62.9)  20 27.3 (10.1–54.6)  19 0.2 
Bacterial vaginosis - 48.7 (36.5–56.6)  139 22.8 (18.3–26.2)  79 < 0.001 
Candida + 47.6 (21.4–60.8) 16 41.32 (12.8–54.6) 9 0.3 
Candida - 44.9 (33.9–55.7) 159 23.72 (20.9–25.4) 144 < 0.001 
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Figure 8. Western blotting of endothelial (e) and inducible (i) nitric oxide synthase (NOS) 
protein expression in cervical samples from women with (+) and without (-) high-risk human 
papillomavirus (HPV) infection.  
 
Thirty-two cervical biopsy samples were randomly selected for immunohistochemistry (16 
with high-risk HPV, 16 without high-risk HPV), in which eNOS was localized in vascular 
endothelium while iNOS was detected typically in basal squamous epithelial cells (Table 5). 
Inflammatory cells were detected in nine women with high-risk HPV and in three women 
without such an infection. None of inflammatory cells in high-risk HPV-negative samples 
stained for iNOS, whereas three high-risk HPV-positive samples stained for it (Table 5, Study 
IV). In positive controls eNOS was localized in vascular epithelium and iNOS in smooth 
muscle and some inflammatory cells, whereas no immunostaining for either eNOS or iNOS 
was seen in the negative controls (Figure 9). 
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Table 5. Immunohistochemical staining intensity of inducible nitric oxide synthase (iNOS) in 
squamous epithelial and inflammatory cells from 32 women with (+) (n = 16) and without (-) 
(n = 16) high-risk human papillomavirus (HPV) infection. The numbers indicate in how many 
samples staining was detected. One sample could show staining in different layers of 
epithelium and/or inflammatory cells. (Study IV). 
(+) = very weak staining, + = weak staining, ++ = moderate staining, +++ = intense staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Squamous epithelial cells Inflammatory 
cells 
 basal parabasal  suprabasal immature 
metaplasia 
  
iNOS  (+) + ++ +++ (+) + + ++ + ++ visible iNOS  
high-risk 
HPV +  
(n = 16) 
3 2 11  4 1 2 1 1 2 9 3 
high-risk 
HPV-  
(n = 16) 
2 6 1 1     2  3  
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Figure 9: Immunohistochemical localization of endothelial nitric oxide synthase (eNOS) (left 
panels, a–c) and inducible nitric oxide synthase (iNOS) (right panels, d–f) in cervical samples 
from women without (a, d) and with (b, e) high-risk human papillomavirus infection. 
Endothelial NOS was localized in the vascular endothelium (black arrow) and iNOS mainly 
in the basal layer of epithelial cells (red arrow). Specimens incubated with irrelevant antibody 
(IgG) showed no immunoreactivity (c, f). Hematoxylin counterstain, × 200 magnification. 
(Study IV). 
 
 
 
 
eNOS iNOS 
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Nitric oxide and persistence of high-risk human papillomavirus infection 
 
High-risk HPV-infected women were followed for 12 months and re-tested for the presence 
of high-risk HPV (Study V). The women with cervical lesions with CIN indicative for Loop 
conization were excluded from predictive analysis. The women with persistent infection had 
higher baseline NOx levels (56.9 μmol/l, 95% CI: 48.7–81.0) compared with those with 
eradicated high-risk HPV (37.7 μmol/l, 95% CI: 27.0–58.0) (p = 0.02). Regarding baseline 
NOx quartiles, the 75th percentile (87 µmol/l) significantly discriminated women with 
detectable and undetectable high-risk HPV at 12 months (p = 0.04). This cut-off value 
predicted high-risk HPV persistence with an OR of 4.1 (p = 0.02) and showed 33% 
sensitivity, 90% specificity, an 85% positive predictive value, a 44% negative predictive 
value, a 10% false-positive rate, and a 67% false-negative rate. A receiver operating 
characteristic curve (solid line) dividing true-positive (sensitivity, y-axis) and false-positive 
(1-specificity, x-axis) results gave an area of 0.62 (95% CI: 0.52–0.69) (p = 0.02) for this cut-
off value (87 µmol/l) in predicting high-risk HPV persistence (Figure 10).  
 
Figure 10. Receiver operating characteristic curve for baseline cervical fluid nitric oxide 
metabolites: 87 µmol/l in differentiating the presence and absence of high-risk human 
papillomavirus after 12 months of follow-up. Broken line = reference line. 
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DISCUSSION 
 
 
Although the causality of high-risk HPV in cervical cancer is one of the strongest in 
epidemiology (Bosch et al. 2008), fortunately most HPV infections are cleared spontaneously 
(Moscicki et al. 2004, Stanley 2010b, Woo et al. 2010). However, the mechanisms leading to 
dysplasia and ultimately to cancer cannot be recognized and thus mass screening by means of 
Pap smears and/or HPV tests, and follow-up are needed. Due to the commonness of HPV 
infection this is laborious and expensive and furthermore may cause unnecessary anxiety in 
women with a transient infection (Maissi et al. 2005). Thus, more information on the course 
of high-risk HPV infection and reliable biomarkers identifying the women with persistent 
high-risk HPV infection are needed. Nitric oxide is a very potent biomediator, and therefore, 
its relationships to HPV infection were studied in this work.  
 
Study population and methods: strengths and limitations 
 
The majority of the women in this study (58%) had high-risk HPV infection, most likely due 
to the fact that many of them had a history of abnormal cervical cytology. As expected, 
women with high-risk HPV were younger than non-infected ones, although more elderly 
women were also included, since another incidence peak of HPV infection is at the age of 
menopause (Burchell et al. 2006). The aim was to study nitric oxide during the natural course 
of HPV infection and thus, women who had undergone Loop conization were excluded from 
the predictive analyses, since it is known that conization is associated with eradication of 
high-risk HPV (Kim et al. 2009, Nam et al. 2009). Pregnant women were also excluded, 
because cervical nitric oxide release is elevated during pregnancy (Väisänen-Tommiska 
2006a). Moreover, women with any cervical bleeding were excluded, since it is known that 
the presence of blood in the sample reduces NOx levels because hemoglobin binds to nitric 
oxide and forms a nitrosylhemoglobin complex (Kankaanranta, et al. 1996). No power 
analyses were carried out in the beginning of the study, since no previous data on the levels of 
cervical fluid NOx in non-pregnant women existed. Although the total number of women 
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tested for the presence of high-risk HPV was high, some subgroups were small and thus the 
data should be interpreted with caution.  
Nitric oxide is converted rapidly to nitrite and nitrate, the levels of which indicate the release 
of nitric oxide in various biological fluids (Miranda et al. 2001). These levels were measured 
by means of a validated method used in several previous studies carried out in our laboratory 
(Ranta, et al. 1999, Väisänen-Tommiska 2006a) and elsewhere (Shaamash et al. 2005). 
Cervical fluid NOx levels do not correlate with plasma NOx levels and are not affected by 
dietary intake of nitrites-containing food (Väisänen-Tommiska 2006a). Thus, no dietary 
restrictions were needed in the women studied. The levels of NOx varied greatly and thus it is 
possible that larger sample sizes would have been needed for additional conclusions. The 
study subjects were not routinely tested for the presence of other cervicovaginal infections, 
although women with clinical signs of infection were excluded. Moreover, the production of 
nitric oxide may change during the course of HPV infection, but it was not possible to 
determine the time at which HPV had been acquired. However, HPV typically first triggers 
low risk cytological changes, followed by different grades of histological changes and thus 
comparison of NOx levels in cytological and histological samples enables some estimation of 
the stage of high-risk HPV infection. 
Two different study populations were used in the present work. One was collected from a 
mass-screening program and the other from a colposcopic unit to which women had been 
referred on the basis of previous Pap smear findings. Levels of cervical fluid NOx differed in 
these groups, presumably because women with history of Pap smear changes probably had 
had HPV infections. However, comparison of HPV-infected and non-infected women was 
carried within each study group and thus this variation does not invalidate the conclusions.  
In addition to NOx assessment the mechanisms behind cervical nitric oxide release were 
eluciated by assessing eNOS and iNOS by both Western blotting and immunohistochemistry. 
Concomitant use of these methods enables quantitative assessment of eNOS and iNOS 
expression and also identification of the location of these activities in cervical cells. To best of 
my knowledge this study is the first one involving Western blots in association with nitric 
oxide and HPV, whereas previous studies have solely involved the use of semi-quantitative 
immunohistochemistry (Hiraku et al. 2007, Mazibrada et al. 2008) (Table 6). I acknowledge 
that the high-risk HPV tests employed could detect only 13 papillomavirus types, although 
approximately 40 other HPV types may infect the genital mucosa (Bosch et al. 2003). Thus, 
women infected with HPV types other than the 13 selected ones tested negatively in the 
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present work. Nevertheless, these 13 types of high-risk HPV cover most of the HVP 
genotypes detected in cervical cancer (Bosch et al. 2003). The tests applied do not allow 
differentiation of high-risk HPV genotypes and therefore, in the follow-up study it was not 
possible to determine if some women were free of the initial infection but had acquired a new 
one. Moreover, two different HPV tests were employed in Study II, but their correlation is 
between 83–89.2 % (Sandri et al. 2006, Carozzi et al. 2007). 
 
Principal findings on human papillomavirus infection 
 
Women with cytological changes suggestive of HPV infection had higher NOx levels 
compared with women with normal cytology. This result was confirmed by the finding that 
women discovered to have high-risk HPV showed elevated cervical NOx levels. Furthermore, 
high-risk HPV infection was associated with elevated expression of both eNOS and iNOS 
proteins. Previous data on HPV and nitric oxide are relatively scant (Table 6). The only in 
vivo study did not show any difference in iNOS immunostaining between various high-risk 
HPV genotypes (Mazibrada et al. 2007). Moreover, HPV seems to suppress the activity of the 
tumor suppressor protein p53 (Wei et al. 2009). In addition, the transduction of HPV 16 
oncoproteins E6 and E7 stimulates iNOS (De Andrea et al. 2005). Thus, these findings give 
further support for the claim that high-risk HPV is capable of directly inducing nitric oxide 
release. This is supported by previous immunohistochemical data (Hiraku et al. 2007, 
Mazibrada et al. 2008) and by my own in vivo findings, which were in accordance with these 
data. Further support for a direct connection between HPV and nitric oxide may be gained 
from the fact the iNOS expression is strongest in basal squamous cells, which are first 
attacked by HPV. On the other hand, it is possible that high-risk HPV induced cytokines, such 
as interferon-γ and tumor necrosis factor-α contribute to nitric oxide release (De Andrea et al. 
2007, Song et al. 2008). This is also supported by the present results showing that high-risk 
HPV induced eNOS expression in vascular endothelium, which is not a target of HPV. 
Perhaps this is mediated through vascular endothelial growth factor (Song et al. 2006, 
Kuemmel et al. 2009, Monk et al. 2010). Furthermore, in the present study inflammatory 
cells, although few in number, showed some iNOS expression. However, this was so little that 
probably high-risk HPV was responsible for iNOS activation.  
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The role of enhanced cervical nitric oxide release during high-risk HPV infection is not clear. 
Nitric oxide inhibits viral replication in vitro (Reiss et al. 1998, Akaike et al. 2000) and thus, 
in the human uterine cervix elevated nitric oxide levels may promote high-risk HPV 
eradication. This is supported by in vitro data showing that macrophages need nitric oxide to 
kill HPV 16 E6 and E7 oncoprotein-expressing cells (Routes et al. 2005). On the other hand, 
cervical nitric oxide could be related to HPV oncogenes E6 and E7, which are dose-
dependently upregulated by nitric oxide (Wei et al. 2009). These oncogenes downregulate 
host tumor suppressor proteins, such as p53 (Hebner et al. 2006), which normally participate 
in regulation of the cell cycle (Hussain et al. 2006). In addition, it is known that high nitric 
oxide levels may damage DNA (Lala et al. 2001). Thus, HPV, by causing nitric oxide release 
and by suppressing p53 may arrest normal cell repair and thus pave the way to the 
development of cancer. It is also possible that nitric oxide has a dual effect in high-risk HPV 
infection and it initially takes part in HPV clearing, but if this fails, nitric oxide may become a 
promoter of disease progression.  
 
Table 6a. Previous in vitro studies on cervical and vaginal nitric oxide, human papillomavirus 
(HPV) and cervical dysplasia. iNOS = inducible nitric oxide synthase, CIN = cervical 
intraepithelial neoplasia. 
Study Method and study setting Main results  
in vitro studies   
De Andrea et al. 
2007 
- Expression of iNOS messenger 
RNA and nitrate/nitrite  levels  
- Normal human keratinocytes 
and an immortalized cell line 
- HPV 16 E6 and E7 oncoproteins 
- HPV 16 oncoproteins E6 and E7 
increase iNOS messeger RNA and 
nitrate/nitrite levels both in normal and 
immortalized cell lines 
Wei et al. 2009 - HPV gene transcription after 
exposure to nitric oxide 
- Tumor suppressor protein p53 
levels after exposure to nitric 
oxide 
- Cells from CIN (HPV 16, HPV 
31), HPV-negative cervical 
carcinoma cells, keratinocytes and 
immortalized cells with normal 
and mutant p53 proteins 
- High nitric oxide concentration 
induces HPV gene (E1, E4, E6, E7) 
RNAs dose-dependently 
- High nitric oxide concentrations 
decrease tumor suppressor protein p53 
levels and activity in HPV-infected 
cells 
- High nitric oxide concentrations 
induce DNA double strand breaks and 
mutations in HPV-positive cells 
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Table 6b. Previous in vivo studies on cervical and vaginal nitric oxide, human papillomavirus 
(HPV) and cervical dysplasia. iNOS = inducible nitric oxide synthase, CIN = cervical 
intraepithelial neoplasia. 
 
Study Method and study setting Main results  
in vivo studies   
Hiraku et al. 
2007 
- Immunohistochemical staining 
of iNOS 
- Women with condyloma 
acuminatum and different grades 
of CIN  
 
- iNOS localization in cytoplasm of 
epithelial cells and stromal 
inflammatory cells 
- iNOS in stroma higher in CIN vs 
condyloma acuminatum 
- iNOS in stroma positively correlated 
with CIN grade 
Tavares-Murta et 
al. 2008 
- Nitric oxide metabolites in 
cervical and vaginal fluid (Griess 
reaction) 
- Women with and without 
bacterial vaginosis, and different 
grades of CIN  
- Nitric oxide metabolites higher in 
cervical fluid vs vaginal secretion 
- Nitric oxide metabolites higher in 
women with CIN vs. bacterial 
vaginosis both in cervix and vagina 
 
Mazibrada et al. 
2008 
- Immunohistochemical staining 
of iNOS 
- Women with normal histology, 
different grades of CIN, or with 
cervical squamous cancer 
 
- No difference in iNOS 
immunostaining between different 
high-risk HPV genotypes 
- iNOS localization in cytoplasm of 
squamous epithelial cells in basal and 
parabasal layers, and inflammatory 
cells    
- Highest iNOS immunostaining in 
women with CIN1 
- iNOS immunostaining significantly 
reduces as the progression of dysplasia 
increases 
 
da Silva et al. 
2010 
- Immunohistochemical staining 
of iNOS 
- Women with normal histology, 
CIN 3, or with invasive cervical 
cancer 
 
- No difference in iNOS 
immunostaining between normal 
histology and CIN 3 
- iNOS immunostaining stronger in 
the stroma of peritumoral region 
compared with normal histology 
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Other relevant gynecological infections 
 
To evaluate nitric oxide release in other cervical and vaginal infections I compared NOx 
levels in women with Chlamydia trachomatis, bacterial vaginosis, and candida with and 
without simultaneous high-risk HPV infection. Neither bacterial vaginosis nor candida 
showed any effect on cervical NOx levels. The data on NOx and candida are novel, but one 
previous study has shown normal levels of NOx in cervical fluid of women with bacterial 
vaginosis (Tavares-Murta et al. 2008). Larger study populations are needed to reveal if 
significant differences truly exist.  
In contrast, Chlamydia trachomatis infection was associated with elevated NOx levels. Both 
iNOS and nitric oxide are related to Chlamydia trachomatis, at least in cell and animal 
experiments. The significance of nitric oxide in connection with Chlamydia trachomatis is 
unknown but it may be a factor in the clearance of infection, or complications; the data are far 
from being uniform in this regard (Chen et al. 1996, Ramsey et al. 2001a, Ramsey et al. 
2001b, Brunham et al. 2005, Roshick et al. 2006, Shao et al. 2010). Moreover, it should be 
emphasized that Chlamydia trachomatis is an independent risk factor of squamous cervical 
cancer (Paavonen et al. 1999, Anttila et al. 2001, Smith et al. 2002b) and thus, it is possible 
that Chlamydia trachomatis-mediated nitric oxide may be involved.  
 
Cervical lesions and nitric oxide  
 
Women with low grade cytological changes showed higher cervical NOx levels compared 
with women with high grade changes. In addition, both eNOS and iNOS expression levels 
were found to be elevated in women with histological cervical lesions. These findings are in 
line with those of other studies (Hiraku et al. 2007, Mazibrada et al. 2008). 
Nitric oxide may have a dual role in immunity and carcinogenesis depending mainly on its 
concentration; high levels may stimulate immune defense and arrest carcinogenesis whereas 
low levels have an opposite effect (Ridnour et al. 2006). Therefore, it is possible that cases of 
mild dysplasia, which are most often cleared spontaneously (Wright et al. 2003), do so with 
the aid of nitric oxide release. In contrast, high-grade dysplasia may progress to cancer 
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perhaps partly because of low nitric oxide release that may result in failed apoptosis (Heller 
2008). The availability of nitric oxide in the cervix may also depend on the duration of HPV 
infection; in the early phase squamous epithelial cells are the primary source of nitric oxide 
(Mazibrada et al. 2008), but in later phases with high grade dysplasia inflammatory and 
stromal cells take over nitric oxide production (Hiraku et al. 2007, Mazibrada et al. 2008, da 
Silva et al. 2010). This may be an additional explanation for high NOx levels in connection 
with mild lesions. 
 
Clinical implications 
 
No reliable biomarkers for high-risk HPV persistence or regression exist. The present data 
indicate that high baseline cervical NOx levels favor high-risk HPV persistence (Study V), 
though the clinical usefulness of NOx testing is restricted as a result of its low sensitivity 
(33%) and high false-positive rate (67%). However, the data indicate that nitric oxide is a 
mediator that reflects the course of high-risk HPV infection and thus nitric oxide is a potential 
target for future studies. It would be particularly interesting to compare nitric oxide levels 
among various high-risk HPV genotypes, since cancerogenic properties of various HPV 
strains vary (Ramanakumar et al. 2010, Schiffman et al. 2011, Stoler et al. 2011). Initial 
studies could perhaps be conducted in cell-line experiments. Moreover, connections between 
cervical nitric oxide and tumor biomarkers, such as p16 and Ki-67 (Kruse et al. 2004, 
Tsoumpou et al. 2009) should be explored. Finally, longitudinal large-scale studies with 
repeated nitric oxide and high-risk HPV sampling are mandatory to assess the prognostic 
value of cervical nitric oxide in the follow-up of HPV-infected women.  
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Figure 11. A schematic summary of the findings in the present study. 
eNOS = enodothelial nitric oxide synthase, iNOS = inducible nitric oxide synthase. 
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CONCLUSIONS 
 
On the basis of the present work the following conclusions can be drawn: 
 
1. Typical HPV-induced cytological abnormalities are accompanied by elevated levels of 
cervical fluid nitric oxide. 
2. Cervical nitric oxide metabolite levels and thus the release of nitric oxide are elevated 
in high-risk human papillomavirus-infected women. 
3. Low-grade cytological changes are accompanied by higher cervical nitric oxide 
metabolite levels compared with high-grade cell abnormalities. 
4. Chlamydia trachomatis infection is associated with elevated cervical fluid nitric oxide 
levels. 
5. In addition to inducible nitric oxide synthase, high-risk human papillomavirus is 
associated with elevated levels of endothelial nitric oxide synthase. 
6. High levels of cervical nitric oxide metabolites may predict the persistence of high-
risk human papillomavirus infection for at least 12 months. 
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